Onur, BahaeddinDemirbas, Hakan BarışGülmez, Arif2024-08-022024-08-022024Onur, B., Demirbas, H. B., & Gülmez, A. (2024). Role of biomarkers in community-acquired pneumonia management. Journal of Acute Disease, 13(3), 87-92. https://doi.org/10.4103/jad.jad_65_242221-61892589-5516https://doi.org/10.4103/jad.jad_65_24https://hdl.handle.net/20.500.13055/742Community-acquired pneumonia (CAP) poses a significant global health threat, particularly affecting vulnerable populations. Biomarkers and scoring systems play a crucial role in diagnosing, assessing severity, and guiding treatment decisions for CAP patients. Biomarkers like C reactive protein, procalcitonin, and the neutrophil-to-lymphocyte ratio aid in diagnosis and severity assessment, while scoring systems such as CURB-65 and Pneumonia Severity Index classify patients into risk categories. Emerging biomarkers (uremia, elevated respiratory rate, hypotension, and age ≥ 65) like serum amyloid A and S100 proteins show promise in predicting disease severity and prognosis. However, further research is needed to determine their precise roles and clinical utility in CAP management.eninfo:eu-repo/semantics/openAccessCURB-65Community-Acquired PneumoniaProcalcitoninAlpha-1 AntitrypsinSerum Amyloid AReview Article10.4103/jad.jad_65_241338792Q4WOS:001276798900005Q3